What is the typical Mazdutide dosage?

Published protocols describe 3–9 mg weekly, given subcutaneous. This is context from the literature, not a recommendation: a licensed provider sets the dose.

What are the side effects of Mazdutide?

Risks noted for Mazdutide include nausea, vomiting, diarrhea, constipation, and heart-rate increase. Tell your provider about your medications and conditions before starting.

What is the half-life of Mazdutide?

The reported half-life is ~7 days (limited data). Onset is typically reported at 2–4 weeks for appetite reduction.

How should Mazdutide be stored?

Refrigerated (2–8 °C); use within the pharmacy beyond-use date.

GLP-1 · PEPTIDE

What is Mazdutide?

Medically reviewed by the G1 Peptides clinical team · Updated October 1, 2026

THE SHORT ANSWER

Mazdutide is a once-weekly injectable that activates the GLP-1 and glucagon receptors. It has been developed mainly in China for weight management and type 2 diabetes and is not approved in the United States.

Mazdutide at a glance

Type: Peptide
Also known as: IBI362, LY3305677
Mechanism: Dual GLP-1 / glucagon receptor agonist
Status: Phase 3
Half-life: ~7 days (limited data)
Route: Subcutaneous
Dosing range in the literature: 3–9 mg weekly
Onset: 2–4 weeks for appetite reduction
Storage: Refrigerated (2–8 °C); use within the pharmacy beyond-use date

How Mazdutide works

The GLP-1 action reduces appetite and improves glucose control. The glucagon action is thought to increase energy expenditure and reduce liver fat.

What Mazdutide is studied for

Weight management
Liver fat reduction
Type 2 diabetes

Phase 3 trials in Chinese adults showed meaningful weight loss and reductions in liver fat. Data in other populations is more limited.

Being studied for something is not proof that it works. Results in individuals vary.

Mazdutide dosing

Published protocols describe 3–9 mg weekly, once weekly, given subcutaneous. Onset is typically reported at 2–4 weeks for appetite reduction.

These figures are context from the literature, not instructions. A licensed provider sets the dose and schedule for each patient.

Mazdutide dosage calculator →

Mazdutide side effects and risks

Nausea
Vomiting
Diarrhea
Constipation
Heart-rate increase

Tell your provider about every medication and condition before starting, and report anything unexpected. See peptide side effects and safety and who should not use peptides.

Is Mazdutide FDA approved?

Developed and submitted for approval in China, where its late-stage trials were run. Not approved by the FDA.

Approval and trial status change. This page was last reviewed on October 1, 2026.

Mazdutide at G1 Peptides

G1 Peptides does not currently supply Mazdutide. A provider can discuss alternatives in a free consultation.

Mazdutide questions

What is Mazdutide?: Mazdutide is a once-weekly injectable that activates the GLP-1 and glucagon receptors. It has been developed mainly in China for weight management and type 2 diabetes and is not approved in the United States.
What is Mazdutide used for?: Mazdutide is studied for weight management, liver fat reduction, and type 2 diabetes. Phase 3 trials in Chinese adults showed meaningful weight loss and reductions in liver fat. Data in other populations is more limited.
How does Mazdutide work?: The GLP-1 action reduces appetite and improves glucose control. The glucagon action is thought to increase energy expenditure and reduce liver fat.
Is Mazdutide FDA approved?: Developed and submitted for approval in China, where its late-stage trials were run. Not approved by the FDA.
What is the typical Mazdutide dosage?: Published protocols describe 3–9 mg weekly, given subcutaneous. This is context from the literature, not a recommendation: a licensed provider sets the dose.
What are the side effects of Mazdutide?: Risks noted for Mazdutide include nausea, vomiting, diarrhea, constipation, and heart-rate increase. Tell your provider about your medications and conditions before starting.
What is the half-life of Mazdutide?: The reported half-life is ~7 days (limited data). Onset is typically reported at 2–4 weeks for appetite reduction.
How should Mazdutide be stored?: Refrigerated (2–8 °C); use within the pharmacy beyond-use date.

For educational purposes only, and not medical advice. These statements have not been evaluated by the FDA. Nothing on this page is intended to diagnose, treat, cure, or prevent any disease. Use any compound only under the guidance of a licensed provider.